The FDA approved the accelerated review for STRO-002 in August 2021, an antibody-drug conjugate anti-FR-α, for the treatment of patients with epithelial ovarian cancer, fallopian tubes, or primary peritoneal cancer resistant to platinum, who have received one to three previous lines of systemic therapy, according to data from the phase I study STRO-001-GM1 [39]. The gene discussed is FOLR1; the disease is ovarian carcinoma.